The ECMO-RESCUE study is a prospective, multicenter, non-randomized, cohort study. In this study, we aimed to assessed whether VA-ECMO treatment can improve the 30-day survival rate of patients with sepsis-induced refractory cardiogenic shock.
All patients who meet inclusion criteria and have no exclusion criteria are considered to be enrolled. During the period of study, the participants can decide whether to accept ECMO based on their personal conditions. If a patient is willing to accept ECMO treatment, we initiate VA-ECMO within 6 hours. Participants taking VA-ECMO during the period of study are referred to as cohort 1, and patients receiving only conventional therapy without ECMO belong to cohort 2. 30-day survival will be accessed to evaluate the survival benefit from ECMO therapy for sepsis-induced refractory cardiogenic shock.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
64
All patients in cohort 1 will initiate ECMO as fast as possible. A maximum of 6 hours is allowed between enrollment and the actual initiation of ECMO. ECMO catheterization and management will be operated by an experienced ECMO team and carried out at the bedside. VA or VAV mode will be chosen according to the patient's condition.
Chen Weiyan
Guangzhou, Guangdong, China
RECRUITING30-day survival
survival rate at day-30
Time frame: From date of enrolled (D0) until date of death from any cause or day-30, whichever came first
ICU survival rate
survival to ICU discharge
Time frame: From date of enrolled (D0) until date of death from any cause or date of discharge from ICU, whichever came first, assessed up to 6 months
hospital survival
survival to hospital discharge
Time frame: From date of enrolled (D0) until date of death from any cause or date of discharge from hospital, whichever came first, assessed up to 6 months
6-month survival
survival rate at 6-month
Time frame: From date of enrolled (D0) until the date of death from any cause or 6-month, whichever came first
quality of life for long-term survival
evaluate through EuroQol Five Dimensions Questionnaire Descriptive System at 6-month within survivors, the minimum value is 3, the maximum value is 15, higher scores mean a worse state.
Time frame: at 6-months
successful rate of ECMO weaning
Successful weaning is defined as maintaining stable condition within 24 hours of ECMO weaning. Analyzed the frequency of patients who weaning ECMO successfully
Time frame: From date of weaning off ECMO until the date of death or 24 hours after ECMO weaning, whichever came first
long-term survivors' cardiac function
LVEF evaluated according to Doppler echocardiography
Time frame: at day-30 and 6-month
the number of days alive without CRRT, mechanical ventilation and vasopressor
the numbers of CRRT-free days, mechanical ventilation-free days and vasopressor-free days
Time frame: between Day 0 and up to Day 30
ICU length of stay (LOS)
ICU LOS
Time frame: From date of enrolled (D0) until the date of death from any cause or discharge from ICU, whichever came first, assessed up to 6 month
hospital length of stay (LOS)
hospital LOS
Time frame: From date of enrolled (D0) until the date of death from any cause or discharge from hospital, whichever came first, assessed up to 6 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.